Skip to content

  • 项目
  • 群组
  • 代码片段
  • 帮助
    • 正在加载...
    • 帮助
    • 为 GitLab 提交贡献
  • 登录/注册
3
3585mind-guard-product-page
  • 项目
    • 项目
    • 详情
    • 活动
    • 周期分析
  • 议题 7
    • 议题 7
    • 列表
    • 看板
    • 标记
    • 里程碑
  • 合并请求 0
    • 合并请求 0
  • CI / CD
    • CI / CD
    • 流水线
    • 作业
    • 计划
  • Wiki
    • Wiki
  • 代码片段
    • 代码片段
  • 成员
    • 成员
  • 折叠边栏
  • 活动
  • 创建新议题
  • 作业
  • 议题看板
  • Luigi Buxton
  • 3585mind-guard-product-page
  • Issues
  • #7

已关闭
未关闭
在 10月 02, 2025 由 Luigi Buxton@luigibuxton236
  • 违规举报
  • 新建问题
举报违规 新建问题

Huperzine A: Dietary Supplements For Brain Health


Huperzine A is a chemical compound that may be remoted from the plant Huperzia serrata (Chinese membership moss), a standard Chinese remedy used for contusions, strains, swelling, and schizophrenia. It can also be made in a laboratory. Huperzine A is commonly listed as "Huperzia serrata extract," "HupA," or "Chinese club moss" on dietary complement product labels. It is usually marketed for Mind Guard testimonials well being and cognitive health supplement efficiency, with claims of enhanced mind guard brain health supplement energy, reminiscence, alertness, attention, concentration, and focus. No reliable scientific proof supports the use of huperzine A to boost cognitive health supplement performance. Multi-ingredient products containing huperzine A might be unsafe. Is it an authorised dietary supplement ingredient? Although it's marketed within the U.S. A is an permitted drug in another nations. For example, huperzine A is on the market in most hospitals in China and is used to "treat" Alzheimer’s disease. Within the U.S., nonetheless, it's unclear whether huperzine A might be legally marketed as a dietary supplement. Is huperzine A effective as a dietary complement?


Thus far, no research have proven huperzine A to enhance cognitive performance in in any other case wholesome people. Preliminary proof suggests huperzine may need useful results on cognitive function among Alzheimer’s illness patients, but extra research is needed to determine this conclusively. Some corporations have been advertising "supplements" containing huperzine A with unlawful claims that their merchandise can "treat" Alzheimer’s. Is huperzine A safe as a dietary supplement? Currently, the Alzheimer’s Association recommends not taking huperzine A, particularly with prescription drugs, as a result of the mixture may enhance the risk of serious side effects. Taking huperzine A together with other dietary complement elements (particularly ones marketed as nootropics) might pose extra well being risks. Overall, security information is lacking and memory and focus supplement lengthy-time period use is not well understood. In addition, multi-ingredient merchandise containing huperzine A have been shown to contain various amounts of huperzine A inconsistent with the brain booster supplement Facts label, in addition to components not allowed in dietary supplements.


Can Military Service Members use huperzine A? Huperzine A is not prohibited to be used by DoD members, and Mind Guard testimonials it is not going to trigger a constructive result on a routine military drug check. However, given the limited evidence of its safety, we advise caution with merchandise that include this ingredient. As well as, some dietary complement merchandise containing huperzine A include substances prohibited to be used. Consuming such ingredients may put your best brain health supplement, profession, or each in danger. In some instances, these ingredients won't be listed on a product’s label, so you might devour prohibited substances unknowingly. Using merchandise that have been third-social gathering certified can assist you to keep away from this risk. Bridwell, R. E., Yoo, M. J., Grove, J. J., & Ng, P. C. (2020). Chest pain from complement use in an active obligation soldier: A case report. Military Medicine, 185(9-10), e1857-e1859. Hao, Z., Liu, Mind Guard testimonials M., Liu, Z., & Lu, D. (2009). Huperzine A for vascular dementia.


Cochrane Database of Systematic Reviews, 2009(2), Article CD007365. Huang, P., Li, B., Guo, Y.-H., Feng, S., Hu, J., & Liu, Q.-Q. 2019). Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: A scientific assessment and meta-evaluation (in Chinese). Jędrejko, K., Catlin, O., Stewart, T., Mind Guard testimonials Anderson, A., Muszyńska, B., Mind Guard testimonials & Catlin, D. H. (2023). Unauthorized substances in "nootropic" dietary supplements: A assessment of the history, pharmacology, prevalence, worldwide laws, and potential as doping brokers. Li, J., Wu, H. M., Zhou, R. L., Liu, G. J., Dong, B. R., & Wu, H. M. (2008). Huperzine A for Alzheimer's illness. Cochrane Database of Systematic Reviews, 2008(2), Article CD005592. Morasch, K. C., Aaron, C. L., Moon, J. E., & Gordon, R. K. (2015). Physiological and neurobehavioral effects of cholinesterase inhibition in healthy adults. Rafii, M. S., Walsh, Mind Guard testimonials S., Little, J. T., Behan, K., Reynolds, B., Ward, C., . Aisen, P. S. (2011). A part II trial of huperzine A in mild to average Alzheimer illness.


Tucker, J., Fischer, T., Upjohn, L., Mazzera, D., & Kumar, M. (2018). Unapproved pharmaceutical ingredients included in dietary supplements associated with U.S. Food and Drug Administration warnings. JAMA Network Open, 1(6), Article e183337. U. S. Food & Drug Administration. 2019). FDA takes motion against 17 corporations for illegally promoting products claiming to treat Alzheimer’s disease. U.S. Food & Drug Administration. 2023). CFSAN antagonistic occasion reporting system (CAERS). Wessinger, C. M., Inman, C. L., Weinstock, J., & Weiss, E. P. (2021). Effect of huperzine A on cognitive perform and perception of effort during exercise: A randomized double-blind crossover trial. Yang, G., Wang, Y., Tian, J., & Liu, J.-P. 2013). Huperzine A for Alzheimer’s disease: A scientific evaluate and meta-analysis of randomized clinical trials. PLoS ONE, 8(9), Article e74916. Yue, J., Dong, B. R., Lin, X., Yang, M., Wu, H. M., & Wu, T. (2012). Huperzine A for mild cognitive impairment. Cochrane Database of Systematic Reviews, 2012(12), Article CD008827.

指派人
分配到
无
里程碑
无
分配里程碑
工时统计
无
截止日期
无截止日期
0
标记
无
指派标记
  • 查看项目标记
引用: luigibuxton236/3585mind-guard-product-page#7